America's Growth Leaders Cytek Biosciences has been recognized by TIME as one of America’s Growth Leaders of 2026. Presented in partnership with global data firm Statista, the ranking recognizes the top-performing publicly listed companies in the United States that have demonstrated exceptional growth, financial stability, and stock performance over the past five years. FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announce ...

Core Insights - Cytek Biosciences, Inc. has been recognized in TIME's 2026 list of America's Growth Leaders, highlighting its exceptional growth, financial stability, and stock performance over the past five years [1][5] - The inclusion in this list signifies Cytek's strong financial foundation and sustained business expansion, particularly in delivering innovative cell analysis solutions [2][5] Company Overview - Cytek Biosciences specializes in high-parameter cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP®) technology to enhance the precision and sensitivity of cell analysis [6] - The company aims to make high-parameter cell analysis more accessible and cost-effective for laboratories of all sizes, addressing urgent challenges in health and scientific research [3][4] Industry Impact - Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, demonstrating their significant impact on global research [4] - The company's innovations support advancements in cancer research, cell and gene therapies, vaccine development, and responses to emerging diseases [3][4]

Core Insights - Cytek Biosciences reported a total revenue of $52.3 million for Q3 2025, reflecting a 2% increase compared to Q3 2024, driven by growth in the US, APAC, and other regions, despite a decline in EMEA [4][10] - The company experienced a GAAP gross profit of $27.6 million, a 5% decrease from the previous year, with a gross profit margin of 53% compared to 56% in Q3 2024 [5][10] - Operating expenses rose to $36.7 million, a 10% increase year-over-year, primarily due to a significant rise in general and administrative expenses [6][8] - The company reported a loss from operations of $9.2 million, compared to a loss of $4.2 million in Q3 2024, and a net loss of $5.5 million compared to a net income of $0.9 million in the same period last year [9][10] - Cytek's total recurring revenue grew by 19% year-over-year, indicating strong performance in service and reagent revenues [10] - The company reaffirmed its 2025 revenue guidance, expecting total revenue to be in the range of $196 million to $205 million, representing a growth of -2% to +2% over 2024 [12] Financial Performance - Total revenue for Q3 2025 was $52.3 million, up from $51.5 million in Q3 2024 [4][10] - GAAP gross profit was $27.6 million, down from $29.0 million in Q3 2024, with a gross profit margin of 53% [5][10] - Operating expenses were $36.7 million, with R&D expenses at $9.0 million (down 9%) and sales and marketing expenses at $11.7 million (down 6%) [6][7] - The net loss for Q3 2025 was $5.5 million, compared to a net income of $0.9 million in Q3 2024 [9][10] Strategic Developments - The installed base of Cytek instruments expanded to 3,456, with 161 new units added in Q3 2025 [10] - The company expanded its European headquarters in Amsterdam, increasing its footprint by over 40% [10] - Cytek's revenue from biotechnology, pharmaceutical, and clinical research organization customers grew by 14% year-over-year [10]

Core Insights - Cytek Biosciences, Inc. will report its financial results for Q3 2025 on November 5, 2025, after market close, followed by a conference call to discuss the results and outlook [1] Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [2] - The company's product offerings include FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Orion™, along with various reagents and software, providing a comprehensive suite of solutions for customers [2] - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [2] Product Usage - Cytek's products are intended for research use only, with specific exceptions for clinical use in China and the European Union for certain systems and reagents [3] Information Distribution - The company utilizes multiple channels, including its website, LinkedIn, and X account, to disseminate material information and comply with disclosure obligations under Regulation FD [4]

Core Insights - Cytek Biosciences has relocated its European headquarters to a new facility in Amsterdam's Life Sciences District, reflecting its commitment to the EMEA region and enhancing service for customers [1][4] - The new site has increased the company's footprint by over 40% and includes a dedicated customer service and training center, providing hands-on training for researchers [2] - The success of Cytek's reagent business is a major driver for this expansion, with the company transitioning warehouse operations in-house to improve operational efficiency and quality control [3] Company Overview - Cytek Biosciences is a leading cell analysis solutions company that utilizes its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [5] - The company's product offerings include various systems and technologies designed to enhance multiplexing capabilities and provide comprehensive solutions for researchers [5] - Cytek's products are primarily for research use, with certain systems available for clinical use in specific regions [6] Strategic Importance - Europe is identified as a key region for Cytek's global growth, and the new Amsterdam facility is expected to enhance the company's capabilities in delivering solutions and services across the EMEA region [4][15] - The expansion aims to support scientific understanding and accelerate data-driven decision-making, fostering innovation within the industry [4]

Core Insights - Cytek Biosciences, a leader in spectral flow cytometry, is set to showcase its advanced solutions at two major industry events, emphasizing the growing demand for deeper cellular insights in cancer research and diagnostics [1][4] Company Overview - Cytek Biosciences specializes in high-resolution, high-content, and high-sensitivity cell analysis tools, utilizing its patented Full Spectrum Profiling™ (FSP) technology [8] - The company's FSP systems have been referenced in over 2,800 peer-reviewed publications, indicating widespread acceptance and application in the research community [2] Technology and Innovation - Cytek's Full Spectrum Profiling™ technology allows for the profiling of more than 40 markers in a single tube, significantly enhancing efficiency and reducing analysis time [7] - The integration of spectral flow cytometry with machine learning is being explored to simplify data analysis and reduce technician workload, as demonstrated in workshops at upcoming conferences [4][6] Industry Events - The European Society for Clinical Cell Analysis (ESCCA) 2025 Conference will take place from September 17 to September 20, 2025, in Montpellier, France, focusing on clinical applications in various fields [3] - The ICCS Annual Meeting & Course will be held from September 28 to September 30, 2025, in Philadelphia, bringing together professionals to advance knowledge in clinical cytometry [5] Leadership and Expertise - Dr. Wenbin Jiang, CEO of Cytek, highlighted the advantages of spectral flow cytometry in enabling laboratories to achieve more with less, thereby allowing scientists to focus on high-skill tasks [7] - Workshops led by experts like Dr. Joseph C. Lownik and Dr. Paul K. Wallace will present innovative approaches to using spectral flow cytometry for accurate diagnosis of leukemia and lymphoma [4][6]

Core Viewpoint - Cytek Biosciences, Inc. will report its financial results for Q2 2025 on August 6, 2025, followed by a conference call to discuss the results and business outlook [1]. Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [2]. - The company's product offerings include FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Orion™, along with various reagents, software, and services [2]. - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [2]. Product Usage - Cytek's products are intended for research use only, with specific exceptions for clinical use in China and the European Union for certain systems and reagents [3]. Information Distribution - The company utilizes its website, LinkedIn, and X (formerly Twitter) for distributing material information and compliance with disclosure obligations under Regulation FD [4].

Core Viewpoint - Cytek Biosciences, Inc. will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, indicating its active engagement in the healthcare investment community [1]. Company Overview - Cytek Biosciences is a leading cell analysis solutions company that specializes in high-resolution, high-content, and high-sensitivity cell analysis through its patented Full Spectrum Profiling™ (FSP) technology [3]. - The company offers a comprehensive suite of products including the Cytek Aurora™, Northern Lights™, and Cytek Orion™ systems, as well as flow cytometers and imaging products under the Amnis and Guava brands [3]. - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [3]. Upcoming Events - Cytek management is scheduled for a fireside chat on June 11 at 11:40 a.m. Pacific Time, which will be accessible via a live and archived webcast on the company's website [2].

Core Insights - Cytek Biosciences reported a total revenue of $41.5 million for Q1 2025, reflecting a 7.6% decrease compared to Q1 2024, primarily due to a slowdown in product sales in the US and EMEA regions, although this was partially offset by growth in the APAC region and strong service revenue globally [4][8] - The company experienced a gross profit of $20.2 million in Q1 2025, which is a 12% decrease from the previous year, resulting in a GAAP gross profit margin of 49% compared to 51% in Q1 2024 [5][20] - Operating expenses increased by 4.1% to $35.1 million, with general and administrative expenses rising significantly from $11.4 million in Q1 2024 to $12.9 million in Q1 2025 [6][7] - The net loss for Q1 2025 was $11.4 million, compared to a net loss of $6.2 million in Q1 2024, indicating a worsening financial position [7][20] - Cytek's cash and marketable securities totaled $265.6 million as of March 31, 2025, down from $277.9 million at the end of 2024, despite share repurchases of $10.6 million during the quarter [9][20] - The company has revised its full-year 2025 revenue guidance to a range of $196 million to $210 million, which represents a potential decline of 2% to growth of 5% compared to 2024 [10] Financial Performance - Total revenue for Q1 2025 was $41.5 million, with product revenue at $28.1 million and service revenue at $13.3 million [20] - Gross profit for the quarter was $20.2 million, leading to a GAAP gross margin of 49% [5][20] - Operating expenses were $35.1 million, with research and development expenses at $9.7 million and sales and marketing expenses remaining flat at $12.5 million [6][20] - The adjusted EBITDA loss for Q1 2025 was $3.3 million, compared to a loss of $0.7 million in Q1 2024 [8][20] Strategic Developments - Cytek expanded its installed base to 3,149 instruments, adding 115 units in Q1 2025, and commenced operations in Singapore to enhance manufacturing capacity [8] - The company launched the Cytek Muse Micro instrument, aimed at providing an affordable option for simplified flow cytometry [8] - Cytek repurchased $10.6 million of its common stock during the first quarter, indicating a commitment to returning value to shareholders [8]

Core Insights - Cytek Biosciences is committed to advancing cell analysis through its patented Full Spectrum Profiling™ (FSP) technology, which will be showcased at key industry events such as CYTO 2025 and IMMUNOLOGY2025 [1][2][5] Company Overview - Cytek Biosciences, Inc. (Nasdaq: CTKB) is a leading company in cell analysis solutions, focusing on high-resolution, high-content, and high-sensitivity tools [6][7] - The company’s FSP technology enhances multiplexing capabilities with precision and sensitivity, positioning it as a pioneer in spectral flow cytometry [6][2] Industry Events - At IMMUNOLOGY2025, Cytek will present its complete cell analysis solutions, including instruments, reagents, and software, aimed at advancing research and discovery [3][4] - The company will also host a workshop on in-depth characterization of mouse immune responses during the event [4] - CYTO 2025 will feature Cytek as a Platinum sponsor, where it will showcase technology designed to accelerate scientific discovery [4][5] Strategic Goals - Cytek aims to make flow cytometry technology more accessible and scalable, unlocking new opportunities in high-growth areas such as immunology, oncology, and cell therapy [2][5] - The company emphasizes its commitment to delivering innovative and flexible solutions to empower researchers and accelerate breakthroughs in scientific advancement [5]